Key facts
- This page summarizes Shelby J. Walker's Form 4 filing for Korro Bio, Inc. (KRRO).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 07 Nov 2023, 21:16.
Shelby J. Walker - 03 Nov 2023 Form 4 Insider Report for Korro Bio, Inc. (KRRO)
- Reporting relationship
- Senior Vice President, General Counsel and Secretary
- Issuer ticker
- KRRO
- Reported as of
- 03 Nov 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 07 Nov 2023, 21:16:09 UTC
- Next SEC filing
- 03 Jul 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Shelby Walker
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Shelby J. Walker filed Form 4 for Korro Bio, Inc. (KRRO) on 07 Nov 2023.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
FREQ
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +23,723
- Change %
- Price
- Shares after
- 23,723
- Date
- 03 Nov 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 23,723
- Exercise price
- $21.94
- Footnotes
- F1, F2, F3, F4
FREQ
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +29,061
- Change %
- Price
- $0.000000
- Shares after
- 29,061
- Date
- 03 Nov 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 29,061
- Exercise price
- $14.98
- Footnotes
- F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
Under the terms of an Agreement and Plan of Merger dated as of July 14, 2023 by and among Korro Bio Ops, Inc. (f/k/a Korro Bio, Inc., "Legacy Korro"), the Issuer (f/k/a Frequency Therapeutics, Inc.) and Frequency Merger Sub, Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"), on November 3, 2023, Merger Sub merged with and into Legacy Korro (the "Merger"), with Legacy Korro surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of Legacy Korro common stock issued under the Korro Bio, Inc.
Footnote F2
(Continued from footnote 1) 2019 Stock Incentive Plan (the "2019 Plan") was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, at an exchange ratio of 0.049688 per share, on the same terms and conditions as were applicable under the 2019 Plan prior to the Merger, after giving effect to a reverse stock split of the Issuer's common stock of 1-for-50. Subsequent to the Merger, the name of the Issuer was changed from Frequency Therapeutics, Inc. to Korro Bio, Inc.
Footnote F3
The shares subject to the option vest as to 25% of the shares on May 8, 2024, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
Footnote F4
Received in exchange for a stock option to acquire 477,453 shares of Legacy Korro common stock issued under the 2019 Plan pursuant to the Merger Agreement.
Footnote F5
The shares subject to the option vest in 48 equal monthly installments commencing from November 3, 2023, subject to the Reporting Person's continued service on each such vesting date.
SEC remarks
Senior Vice President, General Counsel and Secretary